Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage (PACT-PCV)

The Added Value of Recombinant Tissue Plasminogen Activator (rtPA) in Pneumatic Displacement of Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy (PCV) With Concomitant Anti-VEGF Therapy: A Prospective Randomized Controlled Trial

The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).

The main questions it aims to answer are:

  • Does adding rtPA increase the proportion of participants with complete displacement of blood from beneath the fovea, the center of the macula, at 1 week after treatment?
  • Does adding rtPA improve vision at 6 months and reduce complications, particularly vitreous hemorrhage (bleeding into the gel inside the eye) within 1 month after treatment?

Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.

The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.

Participants will:

  • Undergo baseline eye examinations, vision testing, and retinal imaging.
  • Receive injections of anti-VEGF medicine and C3F8 gas into the affected eye, with or without rtPA, according to their assigned group.
  • Follow the prescribed face-down positioning instructions for 3 days after treatment.
  • Attend follow-up visits at 1 week and at 1, 3, and 6 months after treatment for vision testing, eye examinations, and retinal imaging, and receive further anti-VEGF treatment as needed.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

80

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

45 år till 95 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Fovea-involving submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV), with a hemorrhage area of ≥2 optic disc areas and a subfoveal clot thickness of ≥300 μm.
  • An interval of ≤14 days between symptom onset and planned treatment.
  • Willingness to participate in the study and provision of written informed consent.

Exclusion Criteria:

  • Unwillingness to undergo pneumatic displacement (PD).
  • A history of previous SMH.
  • Untreated retinal tears, retinal degenerative lesions, or other ocular conditions that make PD unsuitable.
  • Concurrent significant vitreous hemorrhage that interferes with postoperative examination and treatment outcome assessment.
  • Previous vitrectomy or other ocular surgery that may affect macular structure or the assessment of visual function.
  • Coexisting ocular diseases, such as severe cataract, glaucoma, or uveitis, that may interfere with postoperative visual acuity assessment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Triple PD (Anti-VEGF + Gas + rtPA)

Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement.

Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage.

Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement.

Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms.

Aktiv komparator: Dual PD (Anti-VEGF + Gas)

Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement.

Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage.

Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of complete SMH displacement at 1 week after the procedure.
Tidsram: 1 week after procedure

No residual submacular hemorrhage in the foveal area on OCT.

1 week after procedure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure
Tidsram: Within 1 month after the procedure

Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage.

Within 1 month after the procedure
Incidence of severe postoperative complications, including retinal detachment
Tidsram: Within 3 months after the procedure

Incidence of severe complications after the procedure, including retinal detachment.

Within 3 months after the procedure
Change in best-corrected visual acuity (BCVA) at 6 months
Tidsram: At 6 months after the procedure

Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis.

At 6 months after the procedure
Macular anatomical outcomes at 6 months
Tidsram: At 6 months after the procedure

Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis.

At 6 months after the procedure
Number of anti-VEGF injections within 6 months after the procedure
Tidsram: Within 6 months after the procedure

Total number of anti-VEGF injections administered within 6 months after the procedure.

Within 6 months after the procedure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 januari 2027

Primärt slutförande (Beräknad)

30 juni 2029

Avslutad studie (Beräknad)

31 december 2029

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

17 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera